Tomoaki Hakariya

Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event

There has been no literature which reports a case of interstitial lung disease associated with sorafenib. However, a recent post-marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib. In this article, we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma. Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious interstitial lung disease, although this might depend on racial differences.

Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration‐resistant prostate cancer in men

To elucidate the effect of prior use of ethinylestradiol on enzalutamide treatment for men with castration‐resistant prostate cancer.

Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo-Adjuvant Hormonal Therapy in Prostate Cancer Patients

The anti‐cancer mechanism of neo‐adjuvant hormonal therapy (NHT) is not well understood. Lymphangiogenesis plays an important role in cancer progression and is regulated by a complex mechanism that includes vascular endothelial growth factor (VEGF) signaling. However, there is little information regarding relationship between lymphangiogenesis and androgen deprivation. The aim of this study was to clarify changes in lymphangiogenesis and VEGF expression induced by androgen deprivation in prostate cancer in vivo and in vitro.

Three cases of nonmetastatic prostate cancer treated successfully with primary intermittent androgen deprivation therapy over 10 years

We report three cases of nonmetastatic prostate cancer treated effectively with long‐term primary intermittent androgen deprivation (IAD). IAD is not a standard therapy for patients with nonmetastatic prostate cancer. However, based on our experience, we suggest that IAD is one of useful therapeutic tools under certain patients’ condition.

Complications of ADT for Prostate Cancer: Hot Flashes

Hot flashes are often a lasting and distressing side effect of androgen deprivation therapy (ADT) for men with prostate cancer. Hot flashes have been reported in as many as 80% of men with prostate cancer treated with ADT. In men treated with ADT, endorphins may be reduced because of suppression of testosterone levels. This reduction in endorphins may mediate the process of lowering the thermoregulatory set point and ultimately the activation of heat loss mechanisms, resulting in a hot flash. A variety of treatments have been assessed for managing hot flashes, including hormonal therapies, complementary treatments, and nonhormonal drug treatments, such as clonidine, gabapentin, and selective serotonin reuptake inhibitors. However, for hot flashes, there are presently no highly effective mitigating interventions without adverse events.